A study with human acute myeloid leukemia (AML) cell showed that an activated anti-CD44 antibody (H90) reduced the leukemic repopulation by alteration of the behavior of AML leucocyte stem cells (LSC) by annulling AML LSC homing, resulting in tumor-initiating cell death [64]. Here, CD44 is linked to neoplasm.